Observed Signal · Sep 1, 2026 · Market Signal · Source: St. Jude Children’s Research Hospital · Impact: 3.5/5
AI-informed AdaptiveFlow redefines large-scale cloud computing for drug discovery
See how a machine-learning drug discovery platform for ultra-large virtual screenings called AdaptiveFlow guides the rational selection for deeper exploration
Track St. Jude Children’s Research Hospital Signals & Market Shifts in Real-Time
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your free Explorer workspace to monitor these entities.
Connected Companies & Entities
1 Entity mappedRelated Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
Persistent and NVIDIA Revolutionize Drug Discovery with AI
Persistent Systems announced a collaboration with NVIDIA to accelerate AI-powered solutions for the Healthcare and Life Sciences (HLS) sector, advancing computational drug discovery through generative models and agentic workflows. Persistent has built a Generative Molecules and Virtual Screening solution (GenMoIVS / GenMolVS) that leverages NVIDIA BioNeMo, the NeMo Agent Toolkit and NVIDIA AI Enterprise to run high-fidelity molecular simulation and virtual screening at scale. The solution intends to enable continuous decisioning across virtual screening, candidate prioritization and experimental planning, translating digital simulations into informed wet-lab experiments. Persistent plans to use NVIDIA Nemotron open models and NVIDIA NIM microservices and will deploy on NVIDIA-accelerated compute and servers. The partnership also includes leveraging NVIDIA training resources and certifications to expand Persistent’s AI and LLM engineering capabilities for production-grade deployments in regulated research environments.
Vivodyne builds robotic labs to improve AI drug discovery
Vivodyne, a biotech startup spun out of the University of Pennsylvania, says the AI drug‑discovery field lacks the causal human biological data needed to train useful models and has built HIVE — modular robotic labs that grow human tissues, autonomously dose and monitor them, and generate longitudinal experimental data. The company claims its tissues achieve high concordance with human trial outcomes (e.g., liver 94%, airway 96%, bone marrow 100% on tested chemotherapies), has raised just under $80 million across two rounds led by Khosla Ventures, and last week opened what it calls the world’s largest “human data center” near San Francisco to scale throughput and feed AI research. Vivodyne positions its dataset as a way to enable causal, reinforcement‑learning style models for more predictive human biology and combination‑therapy design.
Anthropic launches AI drug discovery program
Anthropic announced an internal AI-driven drug discovery program focused on treatments for neglected diseases and unveiled Claude Science, an AI workbench aimed at life sciences companies. At a San Francisco event, Anthropic executives said running their own discovery efforts will help build better models and tools to sell to drugmakers. The company did not detail next steps for any drug candidates. The article situates Anthropic’s move within a broader trend of major tech companies (Alphabet, Apple, Amazon) increasing activity in healthcare, and notes Amazon’s acquisitions of One Medical and PillPack now sit in a division called Amazon Health Services.
Track Real-Time Market Signals & Shifts
Set up custom watchlists to receive automated, evidence-grounded executive digests whenever material signals or shifts occur across your tracked landscape.